Amelioration of Liver Fibrosis via In Situ Hepatic Stellate Cell Conversion Through Co‐Inhibition of <scp>TGF</scp> ‐β and <scp>GSK</scp> ‐3 Signalling
SBCH mitigates liver fibrosis through multifaceted mechanisms, including the inhibition of HSC activation, suppression of fibrogenic activity and regulation of key signalling pathways such as PI3K/Akt and EMT. In addition, SBCH induces the trans-differentiation of activated HSCs into hepatocyte-like cells (ciHeps), effectively reducing pathogenic HSCs while increasing functional ciHeps. This dual-target approach not only facilitates liver tissue repair but also restores liver function, offering a promising therapeutic strategy for liver fibrosis and cirrhosis, with potential applications in conditions arising from various aetiologies of liver injury.
Authors
- J. S. Zhang
- Lingting Guan
- Xiangjie Zhu
- Zhi Zhong (ORCID: https://orcid.org/0000-0002-2377-0070)
- Xiuliang Cui (ORCID: https://orcid.org/0000-0002-0165-5020)
- C. Chen (ORCID: https://orcid.org/0000-0002-6562-6659)
- Xiaohua Wu
- Xu Zhang (ORCID: https://orcid.org/0000-0002-4356-0281)
- Weijia Zhang (ORCID: https://orcid.org/0000-0003-2785-6434)
- Jiangchuan Du
- Peilin Zhang (ORCID: https://orcid.org/0000-0003-3874-4948)
- Hongyang Wang (ORCID: https://orcid.org/0000-0002-4709-3334)
- Yanyu Hu
Institutions
- Second Military Medical University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Shanghai Cancer Institute (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
Publication Details
- Journal
- Liver International
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1111/liv.70187
- Citations
- 5
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 6.61
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- National Science and Technology Major Project